All In Biotech

Drug Trial Radar · NCT06754384

Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).

Randomized, Double-blind, Controlled Phase I/II Clinical Trial on the Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Healthy Adults and Children Aged 6 Months to 12 Years.

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Jan 15, 2025

Primary completion

Dec 30, 2025

Study completion Feb 10, 2026

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial aims to assess the tolerability, safety, and immunogenicity of the tetravalent inactivated enterovirus vaccine in adults and children aged 6 months to 12 years. The main questions it aims to answer are: * Phase Ⅰ: The safety of the investigational vaccine in the target population based on adverse events (AEs); * Phase Ⅱ: The immunogenicity of the investigational vaccine in the target population. In Phase I, researchers will compare the safety of the investigational vaccine at low, medium, and high doses with the control vaccine; in Phase II, they will compare the safety and immunogenicity (including immune persistence) of the investigational vaccine at medium and high doses with the control vaccine. Procedure: * In Phase I, will be vaccinated with the investigational vaccine (at low, medium, and high doses) or the control EV71 vaccine/placebo in a 3:1 ratio, following a vaccination schedule of 0 and 1 month. Within each age group, and under the premise of ensuring safety, a dose-escalation trial will be conducted in reverse order of age. * In Phase II, participants in each age group will be randomly assigned to the medium-dose, high-dose investigational vaccine groups, and the control group in a 1:1:1 ratio, receiving two doses of the investigational vaccine or the EV71 vaccine (for ages 6-71 months)/placebo (for ages 6-12 years), with a one-month interval between the two doses. * For all participants in both Phase I and Phase II, immediate reactions within 30 minutes after each dose will be observed. Diary cards/contact cards will be used to collect solicited local and systemic adverse events (AEs) for 0-7 days and unsolicited AEs for 0-30 days after vaccination. Additionally, serious adverse events (SAEs) will be monitored from the start of vaccination until 6 months post-completion of the vaccination schedule. Furthermore, for participants of reproductive age in Phase I, pregnancy events will be collected.

Conditions

  • Hand, Foot, and Mouth Disease (HFMD)
  • Herpangina

Interventions

  • Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)Biological

    Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ)

  • Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)Biological

    Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)

  • High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )Biological

    High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )

  • EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)Biological

    EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)

  • placebo (for ages 6-12 years)Biological

    placebo (for ages 6-12 years)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ⅰ:The safety of the investigational vaccine in the target population based on AR.Time frame: 60 days
  2. Phase Ⅱ:Evaluate the seropositive conversion rates of the investigational vaccine in the target population.Time frame: 60 days
  3. Phase Ⅱ:Evaluate the geometric mean titer (GMT) of the investigational vaccine in the target population.Time frame: 60 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Provincial Center for Disease Control and Prevention

    Hangzhou, Hangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.